On Aug. 6, the US Food and Drug Administration (FDA) granted accelerated marketing approval to avalglucosidase alfa (Nexviazyme) for the treatment of people 1 year of age and older living with late-onset Pompe disease. It is the second approved drug to treat Pompe disease. Nexviazyme will be made available in the US and marketed by Sanofi . . .
Genetic testing has a critical role in patients’ care as genetic information helps physicians to distinguish between types of neuromuscular disorders, informs prognosis and treatment decisions, and determines patients’ eligibility for new and emerging therapies. Selecting the right genetic test and incorporating genetic information to reach a diagnosis and formulate a treatment plan require deep . . .
At MDA, we believe in the power of research and the importance of building relationships among families, clinicians, and the scientists making discoveries to advance treatments and therapies. We invite individuals living with a neuromuscular disease, as well as caregivers and loved ones, to attend MDA Engage symposia taking place across the country. MDA Engage . . .
